🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "major milestone" in the fight against drug-resistant strains of the pathogen, according to health experts.

A Global Public Health Issue

The sexually transmitted infection are increasing around the world, with data suggesting in excess of 82 million infections per year. Particularly high rates are seen in Africa and nations within the WHO's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary advancement in the reality of increasing worldwide cases, increasing antimicrobial resistance and the very limited therapeutic options at this time.”

Medical experts are particularly alarmed about the rise in drug-resistant strains. The WHO has designated it as a "critical concern". A tracking program showed that the effectiveness of primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Drugs Receive Authorization

One new antibiotic, also known as a brand name, was approved by the US Food and Drug Administration in December for combating gonorrhoea. This STI can lead to major issues, including infertility. Researchers hope that specific application of this new drug will help slow the emergence of superbugs.

Gepotidacin, developed by the pharmaceutical company GSK, gained clearance in concurrent days. This medication, which is also used to treat urinary tract infections, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin emerged from a unique collaborative effort for medication research. The non-profit organisation GARDP partnered with the drug firm its industry partner to bring it to fruition.

“This milestone represents a major breakthrough in the treatment of superbug gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Testing Data and Worldwide Availability

Based on results detailed in a prominent scientific publication, zoliflodacin successfully treated the vast majority of uncomplicated infections. This places it at an similar efficacy with the typical regimen, which combines two antibiotics. The study involved over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, the non-profit has the ability to register and commercialise the drug in a wide range of low-income and middle-income countries.

Clinicians on the front lines have voiced hope. The availability of a one-pill regimen such as this is seen as a "game-changer" for gonorrhoea control. This is deemed crucial to alleviate the strain of the disease for individuals and to prevent the spread of extremely resistant gonorrhoea worldwide.